Table 1.
Selected Targeted Therapies for HCC with Trials Underway
| Mechanism | Target | Drug |
|---|---|---|
| Angiogenesis | VEGFR (1–3) | Sorafenib, sunitinib, brivanib, linifanib, BIBF 1120, AZD 2171 (cediranib), TSU68, E7080 |
| VEGF | Bevacizumab | |
| FGFR | Brivanib, BIBF 1120, TSU68 | |
| PDGFR | Sunitinib, sorafenib | |
| Tie-2 | Bay 73-4506, AMG 386 | |
| Signal transduction | EGFR | Erlotinib, cetuximab |
| IGFR | IMC-A12, cixutumumab, BIIB022 | |
| mTOR | Rapamycin, everolimus, temsirolimus, AZD 8055 | |
| c-MET | ARQ 197 | |
| c-KIT | Dasatinib | |
| MEK | AZD 6244 | |
| Apoptosis | TRAIL | Mapatumumab, CS-1008 |
| Chromatin remodeling | HDAC | PDX-101, 4SC 201 |
| Cell migration | SRC | Dasatinib |
Abbreviations: c-MET, mesenchymal epithelial transition factor; HDAC, histone deacetylase; MEK, mitogen-activated protein kinase kinase; SRC, sarcoma viral oncogene homolog; Tie-2, tyrosine kinase with immunoglobulin-like and EGF-like domains 2.